Companies Cryptocurrencies
Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc
Exchange: Nasdaq Global Select
IPO Date: 03/02/2010
CEO: Mr. Mark Mallon
Drug Manufacturers General Specialty & Generic Healthcare 🔗
  • IRWD
  • 11.685
  • 1797597056
    market cap
  • 0.15500069
If you bought

shares of Ironwood Pharmaceuticals Inc (IRWD) on
You would have made
Old Price $12 Current Price $12

Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. The company is headquartered in Boston, Massachusetts and currently employs 515 full-time employees. The firm is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. The company operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. The company is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).

Address: 100 Summer St Ste 2300 Boston MASSACHUSETTS 02110

Stay updated.